Inhibikase Therapeutics Inc (IKT)

Currency in USD
1.4300
-0.1200(-7.74%)
Closed·
After Hours
1.4400+0.0100(+0.70%)
·
IKT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IKT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.41501.5600
52 wk Range
1.12004.2000
Key Statistics
Prev. Close
1.55
Open
1.55
Day's Range
1.415-1.56
52 wk Range
1.12-4.2
Volume
142.88K
Average Volume (3m)
249.03K
1-Year Change
10.85%
Book Value / Share
1.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IKT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.0000
Upside
+459.44%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Inhibikase Therapeutics Inc Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Compare IKT to Peers and Sector

Metrics to compare
IKT
Peers
Sector
Relationship
P/E Ratio
−2.9x−3.1x−0.5x
PEG Ratio
−0.04−0.010.00
Price/Book
1.2x2.2x2.6x
Price / LTM Sales
-9.5x3.3x
Upside (Analyst Target)
-196.4%43.5%
Fair Value Upside
Unlock5.5%6.8%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.0000
(+459.44% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.15 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IKT Income Statement

People Also Watch

5.29
REPL
-3.47%
62.000
CDTX
+0.44%
2.390
CRDF
-0.83%
2.715
ELDN
-1.09%
9.070
CAPR
+12.39%

FAQ

What Stock Exchange Does Inhibikase Trade On?

Inhibikase is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Inhibikase?

The stock symbol for Inhibikase is "IKT."

What Is the Inhibikase Market Cap?

As of today, Inhibikase market cap is 106.31M.

What Is Inhibikase's Earnings Per Share (TTM)?

The Inhibikase EPS (TTM) is -0.82.

From a Technical Analysis Perspective, Is IKT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Inhibikase Stock Split?

Inhibikase has split 1 times.

How Many Employees Does Inhibikase Have?

Inhibikase has 16 employees.

What is the current trading status of Inhibikase (IKT)?

As of 09 Aug 2025, Inhibikase (IKT) is trading at a price of 1.43, with a previous close of 1.55. The stock has fluctuated within a day range of 1.42 to 1.56, while its 52-week range spans from 1.12 to 4.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.